|
Acute Flaccid Myelitis (AFM) Workshop Planning Committee
|
Meeting/ Workshop
|
CDC
|
NICHD, NIAID, NINDS
|
This workshop (planned for May 2020) will bring together research scientists, clinicians, patient advocacy groups, and representatives from relevant organizations to discuss the state-of-the-science for AFM and GBS. The meeting will highlight similarities between the two diseases and facilitate cross-pollination of ideas to advance research, diagnostics, and therapy development for both. Particularly for NICHD, the gaps identified for diagnosis, treatment and management of AFM and it’s consequences in children would inform potential development of future initiatives to address these.
|
|
Adjuvant Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA, ASPR
|
NIAID, NCI
|
Staff from all National Institute of Allergy and Infectious Diseases (NIAID) Divisions, program staff from the Biomedical Advanced Research and Development Authority (BARDA), and regulatory staff from the Food and Drug Administration (FDA) exchange information about ongoing programs related to novel adjuvants for infectious disease vaccines, identify high priority research areas (and gap areas), and discuss ideas to accelerate progress in adjuvant research through better access to information and resources.
|
|
Adolescent Brain Cognitive Development (ABCD) Study
|
Research Initiative
|
CDC
|
NIDA, NCI, NIAAA, NICHD, NIMH, NIMHD, NINDS, OD/DPCPSI/OBSSR
|
The Adolescent Brain Cognitive Development (ABCD) project, a landmark longitudinal study of brain development and child health, will increase our understanding of how diverse experiences during adolescence interact with changing biology to influence brain, cognitive, and social/emotional development of youth. In partnership with area public and private schools, researchers at twenty-one research sites across the country will recruit 10,000 children at age 9-10 from diverse races and ethnicities, education and income levels, and living environments and follow them through their teens and into early adulthood. Throughout this period, researchers will assess each child’s physical and mental health, substance use, sleep patterns, genetics, childhood experiences, and cultural/environmental influences, as well as track brain and cognitive development with non-invasive magnetic resonance imaging scans at regular intervals. To enrich the value of the study, ABCD will release anonymized data annually to the research community in an open science model to allow scientists from all over the world to conduct analyses and pool resources to rapidly expand the types of scientific questions that can be answered. The actionable information coming out of this study will enable education, substance use prevention, and other health promotion policies to ensure the wellbeing and success of the Nation’s children.
|
|
Adolescent Human Immunodeficiency Virus (HIV) Prevention and Treatment Implementation Science Alliance (AHISA)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
FIC, NIAID, NICHD, NIMH, OD/DPCPSI/OAR
|
The Adolescent Human Immunodeficiency Virus(HIV) Prevention and Treatment Implementation Science Alliance (AHISA) aims to enhance the effective use of evidence and help overcome implementation challenges related to prevention, screening, and treatment of HIV among adolescents (ages 15 to 24) in sub-Saharan Africa by catalyzing collaboration and communication among implementation scientists, program implementers, and policymakers. The goals of the Alliance are to: 1) provide a platform for cross-fertilization and exchange of ideas and information among implementation scientists and other stakeholders focusing on different aspects of HIV in adolescents; 2) enable the research to be better informed by programmatic challenges and questions; 3) inform policymakers of promising evidence and encourage use of the data in decision making; and 4) extend the reach and impact of implementation science related to adolescent HIV prevention and treatment.
|
|
Advanced Anticonvulsant System Interagency Product Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
NINDS
|
The Advanced Anticonvulsant System Interagency Product Team is a Department of Defense-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure.
|
|
Advanced Viral Detection Technology IG (AVDTIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
This working group seeks to develop guidelines for best practices for Next Generation Sequencing to identify viral contaminants in biological products.
|
|
Advancing American Kidney Health Initiative
|
Research Initiative
|
CDC, CMS, FDA, ASPE, ASPR, HRSA, IHS, OCR
|
NIDDK, NIEHS
|
This initiative aims to improve the lives of Americans suffering from kidney disease, expand options for American patients, and reduce healthcare costs. The initiative provides specific solutions to deliver on three goals: fewer patients developing kidney failure, fewer Americans receiving dialysis in dialysis centers, and more kidneys available for transplant.
|
|
Advancing Protection and Care for Children in Adversity: A U.S. Government Strategy for International Assistance (APCCA)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
FIC, NICHD, NIMH
|
Interagency working group focused on Advancing Protection and Care for Children in Adversity, with a focus on developing a coordinated US government strategy for international assistance. The National Institutes of Health (NIH) funds research and evidence-based interventions, which often inform the development and refinement of other USG programs aimed at benefiting at-risk children around the globe. Several institutes and centers within the NIH fund research to build knowledge in areas related to APCCA priorities and objectives.
|
|
Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
CC, NHLBI
|
The Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) is a 31-member federal advisory committee that provides advice to the Secretary of Health and Human Services through the Assistant Secretary for Health on a range of policy issues related to blood, blood products, and tissues.
|
|
Advisory Committee on Heritable Disorders in Newborns and Children
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHGRI, NHLBI, NIDDK, NLM
|
The Advisory Committee on Heritable Disorders in Newborns and Children was established under the Public Health Service Act, Title XI, § 1109 (42 USC 300b-10), as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (PL 113-240). The mission of the Advisory Committee on Heritable Disorders in Newborns and Children is to reduce morbidity and mortality in newborns and children who have or are at risk for heritable disorders. The Committee recommends that every newborn screening program include a Uniform Screening Panel that screens for 32 core disorders and 26 secondary disorders. The Committee advises the Secretary, US Department of Health and Human Services on the most appropriate application of universal newborn screening tests, technologies, policies, guidelines, and standards. Specifically, the committee provides to the Secretary, the following: Advice and recommendations concerning grants and projects authorized, awarded, or funded related to screening heritable disorders in newborns and children; technical information to develop Heritable Disorders Program policies and priorities that will enhance the ability of the state and local health agencies to provide screening; counseling and health care services for newborns and children who have or are at risk for heritable disorders, and recommendations; and advice and information to enhance, expand, or improve the ability of the Secretary to reduce mortality and morbidity from heritable disorders in newborns and children. The committee was chartered on May 7, 2015.
|